Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
16 November 2016 Dear Secretariat and Board of the Global Fund, We are writing to you on behalf of Médecins Sans Frontières (MSF) to convey our concerns about the Global Fund’s policies on allocation, co-financing, and transition, as the Board and Secretariat prepare to roll out its next funding allocations to countries.
Last updated 16 November 2016
Civil society statement following the 47th Union World Conference on Lung Health, Liverpool (October 2016) 15 November 2016
Last updated 15 November 2016
October 26, 2016 President Barack Obama The White House 1600 Pennsylvania Avenue NW Washington, DC 20500 Dear President Obama:
Last updated 26 October 2016
24 October 2016 We, Members of the European Parliament Working Group on innovation, access to medicines and poverty-related diseases, would like to express our strong support for the findings and recommendations of the recently released report prepared by the High-Level Panel on Access to Health Technologies1, convened by the United Nations Secretary-General.
Last updated 24 October 2016
An open letter to the sixteen governments negotiating the Regional Comprehensive Economic Partnership (RCEP)
17 October 2016 Health organisations call on trade ministers to reject provisions that would negatively affect access to generic medicines in the Regional Comprehensive Economic Partnership agreement.
Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States”
On 17 June, 2016, all 28 European Union (EU) Health Ministers agreed on Council Conclusions to address the imbalances in the pharmaceutical systems in the EU and its Member States. In these Conclusions, the Ministers invited the European Commission to undertake a critical review of the impact of current intellectual property (IP) related incentives on biomedical innovation.
Last updated 14 September 2016
Mr. Gregg Alton Executive Vice President Corporate and Medical Affairs Gilead Sciences Inc. 333 Lakeside Dr Foster City, CA 94404 Re: Gilead Sciences attempts to remove generic sofosbuvir from Ukraine
Last updated 6 September 2016
30 May 2016 To, China, India, Australia, New Zealand, Myanmar, Lao, Cambodia, Indonesia, Thailand, Vietnam, Malaysia, Brunei, Philippines, Singapore, Japan, South Korea Intellectual Property and Least Developed Countries (LDCs) Protect Transition Period for LDCs
Rohit Malpani, director of policy and analysis at Doctors Without Borders/Médecins Sans Frontières’ (MSF) Access Campaign, delivered the following remarks at Meeting the Challenge of Antimicrobial Resistance, an event hosted by the United Nations’ Every Woman Every Child movement.
MSF welcomes WHO’s Global Health Sector Strategy on HIV and urges Member States to rapidly adopt and implement WHO’s HIV guidelines, particularly the recommendation to provide antiretroviral therapy to all people living with HIV upon diagnosis. Evidence shows ‘treat all’ - also known as test and treat - policies can decrease the risk of developing AIDS by 57%, reduce the risk of sexual transmission by 96%, and give most people living with HIV a life expectancy comparable to HIV-negative people.